skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors

Original Research

(2700) Views  (556) Full article downloads

Authors: Giorgio L Colombo, Sergio Di Matteo, Lluis M Mir

Published Date April 2008 Volume 2008:4(2) Pages 541 - 548
DOI: http://dx.doi.org/10.2147/TCRM.S2780

Giorgio L Colombo1, Sergio Di Matteo1, Lluis M Mir2,3

1S.A.V.E. Studi Analisi Valutazioni Economiche, Milan, Italy; 2CNRS, UMR 8121, Institut Gustave Roussy, Villejuif, France; 3Univ Paris-Sud, UMR 8121, France

Introduction: Tumors of any histological origin can give rise to cutaneous and subcutaneous metastases during follow-up. This study aims to evaluate the costs and benefits of electrochemotherapy (ECT) with the Cliniporator™ vs other currently used methods in the control and treatment of cutaneous and subcutaneous advanced neoplasms.

Materials and methods: A cost-effectiveness analysis was carried out on ECT using the Cliniporator vs other techniques (radiotherapy, hyperthermia associated with radiotherapy and chemotherapy, interferon-alpha, and isolated limb perfusion) for the control and treatment of cutaneous and subcutaneous neoplasms. The direct health costs were attributed a value according to the Italian National Healthcare System. Resource consumption and clinical outcomes were derived from cost survey data collection and literature review.

Results: ECT is cost-effective with an incremental cost effectiveness ratio (ICER) of €1,571.53 to achieve a further additional response. Radiotherapy and interferon-alpha are the least effective strategies. A combination of hyperthermia, chemotherapy, radiotherapy, and interferon-alpha treatment are dominated by ECT (more costly and less effective). Isolated limb perfusion is the most effective treatment, but is very costly (€18,530.47) because of the use of antiblastic drugs (TNFα), with an ICER of €92,717.29.

Conclusions: After sensitivity analysis, the study results confirm the favorable cost-effectiveness ratio of ECT with the Cliniporator and justify its wider use.

Keywords: Cliniporator, cutaneous and subcutaneous tumors, electrochemotherapy, hyperthermia, chemotherapy, radiotherapy, interferon-alpha, isolated limb perfusion, cost-effectiveness






 

Other articles by Professor Giorgio Colombo

Cost-effectiveness analysis of initial HIV treatment under Italian guidelines


A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy
An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis
Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy
Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
Moderate and severe plaque psoriasis: cost-of-illness study in Italy


Readers of this article also read:

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
Review of the combined contraceptive vaginal ring, NuvaRing®
Towards a new standard of perioperative fluid management
Moderate and severe plaque psoriasis: cost-of-illness study in Italy
New approaches to managing asthma: a US perspective
Review of miglustat for clinical management in Gaucher disease type 1
Nonlinear analysis of the heartbeats in public patient ECGs using an automated PD2i algorithm for risk stratification of arrhythmic death
Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy